Fixed-duration ibrutinib–venetoclax versus chlorambucil–obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial

Authors:
Top Cited Papers
Publisher website
Google Scholar
Abstract
No abstract available
Funding Information
  • Janssen Research and Development
  • Janssen Pharmaceuticals Inc

This publication has 27 references indexed in Scilit: